ClinicalTrials.gg
Sign In
Drug

Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014 clinical trials

Also written ES014.

studies test it
4
open now
2
in phase 3
0
first study started
2023

How each study uses Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

ES014
4

Studies by the year they started

4 studies that test it; most in 2023 (2)

Studies that test Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014, by start year
YearStudies
20232
20241
20261

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Desmoid Tumors
1

Who runs them

Industry 3 · Other 1

Elpiscience (Suzhou) Biopharma, Ltd. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Elpiscience Biopharma, Ltd. (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014.

Studies

Open first, then newest update. How each study uses Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 4